Benzinga Digital Content Studio
Detroit, MI --News Direct-- Agile Therapeutics, Inc.
Meet Agile Therapeutics (NASDAQ: AGRX), a women's healthcare company with FDA approval for their weekly women's birth control patch, Twirla®, and who is actively working on a growth strategy to increase their revenue for Q3 of 2022. Learn more about Agile Therapeutics in this interview video with CEO, Al Altomari! Agile Therapeutics is a women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Visit 👉 https://agiletherapeutics.com/
Matt Riley - Head of Investor Relations & Corporate Communications
View original content to download multimedia: https://newsdirect.com/news/nasdaq-agrx-agile-therapeutics-anticipates-increased-growth-in-q3-of-2022-580154414
This news release was distributed by News Direct Corp. (“News Direct”). News Direct is an industry-leading content and news distribution platform. This news release and all materials included within this news release, including, without limitation, all images, trademarks and logos, are protected by copyrights, trademarks, service marks, patents or other proprietary rights and laws. If you copy, broadcast, download, store (in any medium), transmit, show or play any multimedia content from this release in public, you must properly attribute said content to the company or organization from which the news release originated unless otherwise sourced. News Direct makes no warranties with respect to the accuracy or completeness of the information contained in this news release. News Direct hereby disclaims all warranties, whether express, implied, statutory or otherwise, in connection with this news release and the content within this news release.